Tag: global rheumatology therapeutics market

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Rheumatology Therapeutics Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The rheumatology therapeutics market has seen steady expansion in recent years. It is projected to grow from $42.4 billion in 2024 to $44.18 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 4.2%. The historical increase in this market can be ascribed to the increasing prevalence of rheumatologic disorders, a globally expanding aging population, enhanced awareness concerning treatment options, progress in biological therapies, and the broader availability of healthcare services in emerging markets.

The rheumatology therapeutics market is expected to show sustained expansion in the coming years. It is forecast to grow to “$52.25 billion in 2029, achieving a compound annual growth rate (CAGR) of 4.3%.” This projected growth during the forecast period stems from various factors, including the increasing adoption of personalized medicine approaches, the rising use of biosimilars in rheumatology, augmented investment in research and development, the integration of digital health technologies, and regulatory approvals for innovative therapies. Significant trends anticipated in this period encompass the expansion of telemedicine and remote monitoring solutions, the development of more targeted therapies for specific rheumatic conditions, a heightened focus on patient-centric care models, the diversification of biologic treatments beyond monoclonal antibodies, and the implementation of value-based pricing models.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17246&type=smp

What Are The Key Drivers Of Growth In The Rheumatology Therapeutics Market?

The increasing occurrence of autoimmune conditions is anticipated to drive the expansion of the rheumatology therapeutics market in the future. An autoimmune disease refers to a state where the immune system erroneously targets and harms the body’s own tissues. The spread of autoimmune diseases is on the rise, attributed to a mix of genetic, environmental, and lifestyle elements, alongside heightened awareness and better diagnostic methods. Rheumatology treatments are essential for autoimmune diseases to control inflammation, ease symptoms, and stop the damage to joints and tissues resulting from the immune system’s assault on the body. For example, data from June 2024 by the Australian Institute of Health and Welfare, an Australia-based government body, estimated that approximately 514,000 individuals in Australia, representing 2.0% of the population, had rheumatoid arthritis in 2022. Rheumatoid arthritis constituted 2.0% of the total disease burden and 16% of the burden for all musculoskeletal conditions during 2023. Consequently, the growing incidence of autoimmune diseases is fueling the expansion of the rheumatology therapeutics market.

What Are The Key Segments In The Rheumatology Therapeutics Market?

The rheumatology therapeutics market covered in this report is segmented –

1) By Drug Class: Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Disease Indication: Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis, Other Disease Indications

Subsegments:

1) By Disease Modifying Anti-Rheumatic Drugs (DMARDs): Conventional Synthetic DMARDs, Biologic DMARDs, Targeted Synthetic DMARDs

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): COX-2 Inhibitors, Traditional NSAIDs

3) By Corticosteroids: Oral Corticosteroids, Injectable Corticosteroids, Topical Corticosteroids

4) By Uric Acid Drugs: Uric Acid Lowering Agents, Uricosuric Agents, Pegloticase

5) By Other Drug Classes: Immunosuppressants, Biologic Therapies, Analgesics

What Are The Major Trends Driving The Growth Of The Rheumatology Therapeutics Market?

Major companies within the rheumatology therapeutics market are developing innovative solutions, such as intravenous (IV) formulations, to enhance treatment efficacy and patient convenience. An intravenous (IV) formulation refers to a medication or substance administered directly into a vein through a needle or catheter. For instance, in October 2023, Novartis AG, a Switzerland-based pharmaceutical company, announced the US Food and Drug Administration (FDA) had approved Cosentyx, an intravenous (IV) formulation. This form of Cosentyx is uniquely approved to treat adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). It works by specifically targeting and inhibiting interleukin-17A (IL-17A) and is the only non-tumor necrosis factor alpha (TNF-a) IV treatment available for these conditions.

Who Are The Major Companies Operating In The Rheumatology Therapeutics Market?

Major companies operating in the rheumatology therapeutics market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Janssen Biotech, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals, UCB S.A., Galapagos NV (GLPG), Genentech Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Rheumatology Therapeutics Market?

North America was the largest region in the rheumatology therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rheumatology therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Rheumatology Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=17246&type=smp

Browse Through More Reports Similar to the Global Rheumatology Therapeutics Market 2025, By The Business Research Company

Rheumatoid Arthritis Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report

Leukemia Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Bipolar Disorder Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bipolar-disorder-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Cell Therapy Market Evolve in Terms of Growth and Size by 2029?

In recent times, the rheumatology therapeutics market has witnessed a steady escalation in its size. The market, valued at $42.4 billion in 2024, is predicted to reach $44.18 billion in 2025, fueled by a compound annual growth rate (CAGR) of 4.2%. The historical growth in the market is due to the higher instances of rheumatologic disorders, an increase in the global aging population, enhanced awareness regarding treatment alternatives, advancements in biological therapies, and the extension of healthcare accessibility in developing markets.

The market for rheumatology therapeutics is projected to experience consistent expansion in the upcoming years, reaching “$52.25 billion in 2029 with a compound annual growth rate (CAGR) of 4.3%. Prospective growth in this period is linked to the adoption of personalized medicine, increased use of biosimilars in rheumatology, a surge in research and development investments, the incorporation of digital healthcare tech, and the green light for new therapy alternatives. Core trends for this predicted period encompass the rise in telemedicine and remote patient monitoring solutions, the broadening of targeted treatments for particular rheumatic conditions, prioritization of patient-focused care strategies, enlargement of biologic therapies beyond monoclonal antibodies, and the uptake of value-driven pricing structures.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17246&type=smp

What factors are expected to fuel Cell Therapy market growth in the coming years?

The surge in chronic diseases has contributed to the growth of the cell therapy market. The US Centers for Disease Control and Prevention (CDC) characterizes chronic disease as an illness lasting a year or more that necessitates medical care, hinders daily activities, or both. This includes conditions like heart disease, cancer, diabetes, and Parkinson’s disease. Stem cells have the potential to assist patients with conditions such as spinal cord injuries, type 1 diabetes, Parkinson’s disease, heart disease, cancer, and osteoarthritis. As an illustration, in July 2024, the Centers for Disease Control and Prevention (CDC), a national public health organization in the U.S., disclosed significant advancements in public health initiatives. Heart disease or stroke lead to the death of over 944,800 Americans annually, representing more than one-third of all deaths. In the U.S., yearly cancer diagnoses are approximately 1.7 million individuals, with over 600,000 ultimately succumbing to the disease, making it the second leading cause of death. Furthermore, over 38 million Americans have diabetes, and another 98 million adults are prediabetic, thus increasing their potential for developing type 2 diabetes. Diabetes can trigger serious complications like heart disease, renal failure, and blindness. Meanwhile, obesity affects 20% of children and 42% of adults, thereby increasing susceptibility to chronic diseases such as type 2 diabetes, heart disease, and certain cancers. The escalating prevalence of chronic diseases has intensified the need for cell therapies, thereby facilitating the expansion of the cell therapy market.

The rheumatology therapeutics market covered in this report is segmented –

1) By Drug Class: Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Disease Indication: Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis, Other Disease Indications

Subsegments:

1) By Disease Modifying Anti-Rheumatic Drugs (DMARDs): Conventional Synthetic DMARDs, Biologic DMARDs, Targeted Synthetic DMARDs

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): COX-2 Inhibitors, Traditional NSAIDs

3) By Corticosteroids: Oral Corticosteroids, Injectable Corticosteroids, Topical Corticosteroids

4) By Uric Acid Drugs: Uric Acid Lowering Agents, Uricosuric Agents, Pegloticase

5) By Other Drug Classes: Immunosuppressants, Biologic Therapies, Analgesics

What Trends Are Currently Influencing Growth In The Cell Therapy Market?

Top-tier firms in the rheumatology therapeutics market are focusing on the development of innovative solutions, such as intravenous (IV) formulations. This strategy is intended to boost treatment effectiveness and improve patient experience. IV formulations involve the direct administration of medication or substances into a vein using a needle or catheter. For example, in October 2023, the US Food and Drug Administration (FDA) granted approval to Cosentyx, an IV formulation from Novartis AG, a renowned pharmaceutical company based in Switzerland. This particular version of Cosentyx has the exclusive approval for treating adult patients with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). By specifically blocking interleukin-17A (IL-17A), it serves as the sole non-tumor necrosis factor alpha (TNF-a) IV treatment option for these diseases.

What Are The Most Active Companies In The Cell Therapy Market Today?

Major companies operating in the rheumatology therapeutics market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Janssen Biotech, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals, UCB S.A., Galapagos NV (GLPG), Genentech Inc.

https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

Which Regional Markets Are Attracting The Most Investment In Cell Therapy?

North America was the largest region in the rheumatology therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rheumatology therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=17246&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Rheumatology Therapeutics Market Expected to Grow Between 2025 And 2029?

The market size for rheumatology therapeutics has seen consistent growth over the past few years. The current projection indicates an increase from $42.4 billion in 2024 to $44.18 billion in 2025, showcasing a compound annual growth rate (CAGR) of 4.2%. The historical growth can be credited to the increasing incidence of rheumatologic conditions, a growing aging population worldwide, heightened awareness of potential treatment solutions, progress in biological therapies, and the enhancement of healthcare availability in developing markets.

Anticipations indicate that the rheumatology therapeutics market will undergo steady expansion in the coming years. The market is predicted to reach $52.25 billion by 2029, growing at an annual average rate of 4.3%. This projected growth during the forecasted period can be credited to factors like the increasing switch to personalized medicine, growing utilization of biosimilars in rheumatology, an upsurge in research and development investment, the unification of digital health technologies, and accreditation for new therapies. Notable trends within this period encompass the proliferation of telemedicine and remote monitoring solutions, broadening of targeted treatments for specific rheumatic conditions, focus on patient-focused care models, widening of biologic treatments beyond monoclonal antibodies, and the embracing of value-based pricing models.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17246&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Rheumatology Therapeutics Market?

The growth of the rheumatology therapeutics market is anticipated to be driven by the mounting occurrence of autoimmune diseases. These diseases have the characteristic where the immune system erroneously damages the body’s tissues. The increasing incidence of such diseases can be attributed to a mix of genetics, environmental influencers, lifestyle elements, enhanced awareness, and better diagnostic skills. Rheumatology therapeutics are vital in managing autoimmune diseases as they control inflammation, relieve symptoms, and prevent damage to joints and tissues caused by the immune system assaulting the body. For example, the Australian Institute of Health and Welfare estimated in June 2024 that around 514,000 individuals, accounting for 2.0% of the Australian population, were living with rheumatoid arthritis in 2022. This disease represented 2.0% of the entire disease load and 16% of the load for all musculoskeletal conditions in 2023. Therefore, due to the escalating incidence of autoimmune diseases, the rheumatology therapeutics market is witnessing growth.

Which Primary Segments of the Rheumatology Therapeutics Market Are Driving Growth and Industry Transformations?

The rheumatology therapeutics market covered in this report is segmented –

1) By Drug Class: Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Disease Indication: Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis, Other Disease Indications

Subsegments:

1) By Disease Modifying Anti-Rheumatic Drugs (DMARDs): Conventional Synthetic DMARDs, Biologic DMARDs, Targeted Synthetic DMARDs

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): COX-2 Inhibitors, Traditional NSAIDs

3) By Corticosteroids: Oral Corticosteroids, Injectable Corticosteroids, Topical Corticosteroids

4) By Uric Acid Drugs: Uric Acid Lowering Agents, Uricosuric Agents, Pegloticase

5) By Other Drug Classes: Immunosuppressants, Biologic Therapies, Analgesics

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=17246&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Rheumatology Therapeutics Market?# Market?

North America was the largest region in the rheumatology therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rheumatology therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Rheumatology Therapeutics Market?

The rheumatology therapeutics market is seeing significant developments by leading companies who are creating unique solutions such as intravenous (IV) formulations to improve treatment effectiveness and patient experience. IV formulations refer to drugs or substances delivered straight into a vein via a needle or tube. One notable development occurred in October 2023, when Swiss pharmaceutical company Novartis AG publicized they had received approval from the US Food and Drug Administration (FDA) for their IV formulation – Cosentyx. The specific form of Cosentyx is exclusively approved for treating adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). It functions by directly targeting and slowing down interleukin-17A (IL-17A) and is the sole non-tumor necrosis factor alpha (TNF-a) IV treatment option available for these ailments.

View the full report here:

https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

What Parameters Are Used to Define the Rheumatology Therapeutics Market?

Rheumatology therapeutics encompass treatments aimed at managing and alleviating symptoms of rheumatic diseases, such as arthritis, lupus, and gout. These therapies include medications, such as anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs), and biologics, as well as physical therapy and lifestyle modifications. The goal is to reduce inflammation, control pain, and improve the quality of life for patients.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17246

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Rheumatology Therapeutics Market Growth Performance Trended Historically, And What Lies Ahead?_x000D_

In recent times, there has been a robust expansion in the size of the rheumatology therapeutics market. A growth from $42.4 billion in 2024 to $44.61 billion in 2025 is projected, maintaining a compound annual growth rate (CAGR) of 5.2%. Factors contributing to the growth during the historical period include an increase in the occurrence of rheumatologic disorders, a surge in the global aging population, heightened awareness of available treatment options, advancements in biological therapy, and widening access to healthcare in burgeoning markets._x000D_

_x000D_

#What Is the Forecast for the Rheumatology Therapeutics Market Size Through 2029?#_x000D_

The market size for rheumatology therapeutics is projected to experience consistent expansion in the coming years, reaching an estimated value of $53.88 billion in 2029 at a CAGR of 4.8%. The growth predicted for this period is associated with the transition to personalized medicine, increased implementation of biosimilars in rheumatology, amplified investment in R&D, the incorporation of digital health technology, and the regulatory approval of new therapies. During the forecast period, significant trends include the increasing use of telemedicine and remote monitoring, the introduction of targeted treatments for specific rheumatic ailments, a focus on patient-oriented care models, broadening the use of biologic treatments beyond monoclonal antibodies, and the application of value-based pricing models._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=17246&type=smp_x000D_

_x000D_

#What are the Key Market Players in Rheumatology Therapeutics Market and How They’re Evolving?#_x000D_

Major companies operating in the rheumatology therapeutics market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Janssen Biotech, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals, UCB S.A., Galapagos NV (GLPG), Genentech Inc._x000D_

_x000D_

#What Are the Primary Growth Drivers in the Rheumatology Therapeutics Market?#_x000D_

The escalating occurrence of autoimmune disorders is predicted to drive the expansion of the rheumatology therapeutics market. Autoimmune diseases are conditions where the body’s immune system mistakenly launches an attack on its own tissues. The surging incidence of these disorders is attributed to a blend of genetic, environmental, and lifestyle factors, in addition to heightened awareness and enhanced diagnosis abilities. Autoimmune conditions necessitate rheumatology therapeutics to handle inflammation, ease symptoms, and thwart damage to joints and tissues resulting from the body’s immune system assault. For instance, in June 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, estimated that around 514,000 Australians, or 2.0% of the population, lived with rheumatoid arthritis in 2022. In 2023, rheumatoid arthritis accounted for 2.0% of total disease burden and 16% of all musculoskeletal condition burdens. Hence, the escalating occurrence of autoimmune diseases fuels the growth of the rheumatology therapeutics market._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=17246&type=smp_x000D_

_x000D_

#What Are the Leading Segments in the Global Rheumatology Therapeutics Industry?#_x000D_

The rheumatology therapeutics market covered in this report is segmented –_x000D_

_x000D_

1) By Drug Class: Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes_x000D_

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy_x000D_

3) By Disease Indication: Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis, Other Disease Indications_x000D_

_x000D_

Subsegments:_x000D_

1) By Disease Modifying Anti-Rheumatic Drugs (DMARDs): Conventional Synthetic DMARDs, Biologic DMARDs, Targeted Synthetic DMARDs_x000D_

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): COX-2 Inhibitors, Traditional NSAIDs_x000D_

3) By Corticosteroids: Oral Corticosteroids, Injectable Corticosteroids, Topical Corticosteroids_x000D_

4) By Uric Acid Drugs: Uric Acid Lowering Agents, Uricosuric Agents, Pegloticase_x000D_

5) By Other Drug Classes: Immunosuppressants, Biologic Therapies, Analgesics_x000D_

_x000D_

#What Are the Key Market Trends in the Rheumatology Therapeutics Industry?#_x000D_

Major players in the rheumatology therapeutics market are creating novel solutions like intravenous (IV) formulations to improve treatment effectiveness and patient convenience. IV formulations are medicines or substances directly introduced into a vein via a needle or catheter. For example, the US Food and Drug administration (FDA) gave its approval to Cosentyx, an IV formulation developed by Novartis AG, a pharmaceutical firm based in Switzerland in October 2023. This unique version of Cosentyx is designed for treating adults suffering from psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). It functions by particularly targeting and impeding interleukin-17A (IL-17A), making it the sole non-tumor necrosis factor alpha (TNF-a) IV treatment for these diseases._x000D_

_x000D_

#Access The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report_x000D_

_x000D_

#What Is the Regional Outlook for the Rheumatology Therapeutics Market?#_x000D_

North America was the largest region in the rheumatology therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rheumatology therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Purchase The Full Report Today:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17246_x000D_

_x000D_

#This Report Delivers Insight On: #_x000D_

1. How big is the rheumatology therapeutics market, and how is it changing globally?_x000D_

2. Who are the major companies in the rheumatology therapeutics market, and how are they performing?_x000D_

3. What are the key opportunities and risks in the rheumatology therapeutics market right now?_x000D_

4. Which products or customer segments are growing the most in the rheumatology therapeutics market?_x000D_

5. What factors are helping or slowing down the growth of the rheumatology therapeutics market?_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 2071930708_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the rheumatology therapeutics industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Key Milestones in the Rheumatology Therapeutics Market’s Growth Trajectory From 2025 To 2034?

Recent years have seen a robust growth in the size of the rheumatology therapeutics market. The market is projected to expand from its worth of $42.4 billion in 2024 to a value of $44.61 billion in 2025, achieving a compound annual growth rate (CAGR) of 5.2%. Several factors contribute to this growth during the historical period, including an increased incidence of rheumatologic disorders, growth in the global aging population, better awareness concerning treatment alternatives, progress in biological therapies, and broader access to healthcare in burgeoning markets.

Expectations are set for the rheumatology therapeutics market size to experience consistent expansion in the upcoming years. Rising to $53.88 billion in 2029 with a compound annual growth rate (CAGR) of 4.8%, this growth occurring within the forecast period can be credited to various factors such as the shift towards individualized medical treatments, increased usage of biosimilars in rheumatology, an uptick in research and development investment, incorporation of digital health tech, and authorization of innovative therapies by regulatory authorities. Primary trends to anticipate in this forecast period encompass the advancement in telemedicine and distant monitoring solutions, the broadening of targeted therapies for specific rheumatic diseases, focus on patient-oriented care models, extension of biologic treatments beyond monoclonal antibodies, and the inclusion of value-oriented pricing models.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17246&type=smp

What Are the Core Growth Drivers Propelling the Rheumatology Therapeutics Market Forward?

The increasing occurrence of autoimmune diseases is anticipated to drive the expansion of the rheumatology therapeutics market in the future. A condition wherein the immune system erroneously attacks and harms the body’s tissues is known as an autoimmune disease. The growing occurrences of autoimmune diseases are attributed to a combination of genetic, environmental, and lifestyle factors, as well as heightened awareness and improved diagnostic techniques. Rheumatology therapeutics are crucial to manage inflammation, relieve symptoms, and inhibit joint and tissue damage resulting from the body being attacked by the immune system in the case of autoimmune diseases. For example, the Australian Institute of Health and Welfare, a government agency based in Australia, reported in June 2024 that approximately 514,000 people, or 2.0% of the population in Australia, were projected to be living with rheumatoid arthritis in 2022. Rheumatoid arthritis accounted for 2.0% of the entire disease load and 16% of the load for all musculoskeletal conditions in 2023. Therefore, the surging occurrences of autoimmune diseases are propelling the expansion of the rheumatology therapeutics market.

Which Segments in the Rheumatology Therapeutics Offer the Most Growth?

The rheumatology therapeutics market covered in this report is segmented –

1) By Drug Class: Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Disease Indication: Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis, Other Disease Indications

Subsegments:

1) By Disease Modifying Anti-Rheumatic Drugs (DMARDs): Conventional Synthetic DMARDs, Biologic DMARDs, Targeted Synthetic DMARDs

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): COX-2 Inhibitors, Traditional NSAIDs

3) By Corticosteroids: Oral Corticosteroids, Injectable Corticosteroids, Topical Corticosteroids

4) By Uric Acid Drugs: Uric Acid Lowering Agents, Uricosuric Agents, Pegloticase

5) By Other Drug Classes: Immunosuppressants, Biologic Therapies, Analgesics

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=17246&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Rheumatology Therapeutics Market?

North America was the largest region in the rheumatology therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rheumatology therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Rheumatology Therapeutics Market?

Key players in the rheumatology therapeutics marketplace are pioneering new solutions such as intravenous (IV) formulations to improve the effectiveness of treatments and provide greater convenience for patients. Intravenous (IV) formulation is a process where a drug or substance is directly infused into the vein via a needle or catheter. For instance, in October 2023, Switzerland-based pharma giant Novartis AG made the announcement that their intravenous (IV) formulation, Cosentyx, had received approval from the US Food and Drug Administration (FDA). This particular version of Cosentyx has been uniquely approved for the treatment of adults suffering from psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). It functions by specifically aiming at and hindering the interleukin-17A (IL-17A), and stands as the only non-tumor necrosis factor alpha (TNF-α) IV therapy available for these particular conditions.

View the full report here:

https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

What Are the Key Elements That Define the Rheumatology Therapeutics Market?

Rheumatology therapeutics encompass treatments aimed at managing and alleviating symptoms of rheumatic diseases, such as arthritis, lupus, and gout. These therapies include medications, such as anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs), and biologics, as well as physical therapy and lifestyle modifications. The goal is to reduce inflammation, control pain, and improve the quality of life for patients.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17246

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the rheumatology therapeutics market size evolved in recent years?

The market for rheumatology therapeutics has been on a steady upward trajectory in the past few years. Starting from a valuation of $42.4 billion in 2024, it is projected to ascend to $44.61 billion in 2025, charting an impressive compound annual growth rate (CAGR) of 5.2%. The dynamic growth seen during this period is linked to several factors – a surge in the occurrence of rheumatologic conditions, a globally aging population, increased cognizance of available treatments, progress in biological therapies, and amplified healthcare reach in burgeoning markets.

What are the predictions for the rheumatology therapeutics market size in the coming years?

The rheumatology therapeutics market size is expected to see steady growth in the next few years. It will grow to $53.88 billion in 2029 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to the shift towards personalized medicine approaches, rising adoption of biosimilars in rheumatology, increasing investment in research and development, integration of digital health technologies, and regulatory approvals for novel therapies. Major trends in the forecast period include growth in telemedicine and remote monitoring solutions, expansion of targeted therapies for specific rheumatic conditions, emphasis on patient-centric care models, expansion of biologic treatments beyond monoclonal antibodies, and adoption of value-based pricing models.

Get your rheumatology therapeutics market report here!

https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

What key factors are fueling the growth of the rheumatology therapeutics market?

The increase in autoimmune diseases is predicted to stimulate the expansion of the rheumatology therapeutics market. Autoimmune diseases, in which the body’s immune system erroneously harms its own tissues, are witnessing a surge due to a mix of genetic, environmental, and lifestyle influences, along with heightened awareness and enhanced diagnostic skills. Rheumatology therapeutics are essential for treating these diseases to manage inflammation, relieve symptoms, and prevent damage to joints and tissue from the body’s own immune system attack. For example, the Australian Institute of Health and Welfare, a government agency in Australia, reported that approximately 514,000 people in Australia, accounting for 2.0% of the population, were expected to have rheumatoid arthritis by 2022. By 2023, rheumatoid arthritis represented 2.0% of the overall disease load and 16% of the total burden related to all musculoskeletal conditions. As a result, the increasing incidence of autoimmune diseases is fueling the development of the rheumatology therapeutics market.

How is the global rheumatology therapeutics market divided into key segments?

The rheumatology therapeutics market covered in this report is segmented –

1) By Drug Class: Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Disease Indication: Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis, Other Disease Indications

Subsegments:

1) By Disease Modifying Anti-Rheumatic Drugs (DMARDs): Conventional Synthetic DMARDs, Biologic DMARDs, Targeted Synthetic DMARDs

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): COX-2 Inhibitors, Traditional NSAIDs

3) By Corticosteroids: Oral Corticosteroids, Injectable Corticosteroids, Topical Corticosteroids

4) By Uric Acid Drugs: Uric Acid Lowering Agents, Uricosuric Agents, Pegloticase

5) By Other Drug Classes: Immunosuppressants, Biologic Therapies, Analgesics

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17246&type=smp

Who are the key firms paving the way for growth in the rheumatology therapeutics market?

Major companies operating in the rheumatology therapeutics market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Janssen Biotech, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals, UCB S.A., Galapagos NV (GLPG), Genentech Inc.

What emerging trends are influencing the growth of the rheumatology therapeutics market?

Leading firms in the rheumatology therapeutics market are pioneering the creation of inventive solutions like intravenous (IV) formulations to boost both the effectiveness of the treatment and patient ease. The term intravenous (IV) formulation pertains to medications or substances administered right into the vein via a catheter or needle. For example, Novartis AG, a pharmaceutical company originating from Switzerland, reported in October 2023 that Cosentyx, an IV formulation, gained approval from the US Food and Drug Administration (FDA). This particular variant of Cosentyx has been exclusively approved to provide treatment for adults suffering from psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). Its mechanism of action involves targeting and inhibiting interleukin-17A (IL-17A) specifically, distinguishing it as the solo non-tumor necrosis factor alpha (TNF-a) IV therapy accessible for these ailments.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17246

What regions are contributing significantly to the growth of the rheumatology therapeutics market?

North America was the largest region in the rheumatology therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rheumatology therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Cystic Fibrosis (CF) Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cystic-fibrosis-cf-therapeutics-global-market-report

Hepatitis Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

Peptide Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Long-Term Growth Rate is Expected for the Rheumatology Therapeutics Market Between 2025 and 2034?

The market for rheumatology therapeutics has seen considerable growth in previous years. It is predicted to expand from $42.4 billion in 2024 to $44.61 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.2%. Factors contributing to this historical growth include a higher incidence of rheumatologic conditions, a surge in the global elderly population, enhanced knowledge of treatment alternatives, advances in biological treatment methods, and widened access to healthcare in burgeoning markets.

In the coming years, the rheumatology therapeutics market is projected to experience consistent growth, with its value predicted to reach $53.88 billion by 2029, at a compound annual growth rate (CAGR) of 4.8%. This growth for the upcoming years can be linked to the shift towards more individualized medicine strategies, increased use of biosimilars in rheumatology, amplified investment in research and development, incorporation of digital health tech, and the approval of innovative therapies by regulators. In the projection period, key trends to watch include the growth of telemedicine and distant observation solutions, the widening of targeted therapies for specific rheumatic disorders, a focus on care models that prioritize the patient, the extension of biologic treatments beyond monoclonal antibodies, and the adoption of value-based pricing models.

Which Factors Are Enhancing the Growth of the Rheumatology Therapeutics Market?

The escalation in the frequency of autoimmune diseases is anticipated to accelerate the expansion of the rheumatology therapeutics market in the future. Autoimmune diseases arise when the immune system erroneously harms the body’s own tissues. This mounting occurrence is due to an amalgamation of genetic, environmental, and lifestyle influences, coupled with heightened awareness and advanced diagnostic capabilities. There is a need for rheumatology therapeutics to control inflammation, relieve symptoms and stave off damage to joints and tissues caused by the immune system’s assault on the body in autoimmune diseases. For example, the Australian Institute of Health and Welfare, a government agency based in Australia, revealed in June 2024 that approximately 514,000 inhabitants of Australia, translating to 2.0% of the population, were thought to be suffering from rheumatoid arthritis back in 2022. The burden of this ailment represented 2.0% of the total disease load and 16% of the burden from all musculoskeletal disorders in 2023. Hence, the upward trend in the incidence of autoimmune diseases is fuelling the surge of the rheumatology therapeutics market.

Get Your Free Sample of the Global Rheumatology Therapeutics Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=17246&type=smp

What Are the Key Firms That Are Driving Transformation in the Rheumatology Therapeutics Market?

Major companies operating in the rheumatology therapeutics market are:

• Pfizer Inc.

• Johnson & Johnson

• Roche Holding AG

• Merck & Co. Inc.

• AbbVie Inc.

What Current Trends in the Rheumatology Therapeutics Market Should Industry Players Pay Attention To?

Leading firms in the rheumatology therapeutics market are transforming therapy effectiveness and patient comfort by introducing novel solutions like intravenous (IV) formulations. IV formulations are medications or substances directly applied into a vein using a needle or a catheter. For instance, a development in October 2023 by the Swiss pharmaceutical firm Novartis AG saw the US Food and Drug Administration (FDA) approval of Cosentyx, an IV formulation. This version of Cosentyx received exclusive endorsement for use in adults suffering from psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). It operates by selectively inhibiting interleukin-17A (IL-17A) and remains the only non-tumor necrosis factor alpha (TNF-α) IV therapy for these disorders.

Get Instant Access to the Global Rheumatology Therapeutics Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

Which Segments Play a Crucial Role in the Expansion of the Rheumatology Therapeutics Market?

The rheumatology therapeutics market covered in this report is segmented –

1) By Drug Class: Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Disease Indication: Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis, Other Disease Indications

Subsegments:

1) By Disease Modifying Anti-Rheumatic Drugs (DMARDs): Conventional Synthetic DMARDs, Biologic DMARDs, Targeted Synthetic DMARDs

2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): COX-2 Inhibitors, Traditional NSAIDs

3) By Corticosteroids: Oral Corticosteroids, Injectable Corticosteroids, Topical Corticosteroids

4) By Uric Acid Drugs: Uric Acid Lowering Agents, Uricosuric Agents, Pegloticase

5) By Other Drug Classes: Immunosuppressants, Biologic Therapies, Analgesics

What Regions Are Driving Expansion in the Rheumatology Therapeutics Market?

North America was the largest region in the rheumatology therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rheumatology therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Parameters Define the Rheumatology Therapeutics Market’s Scope?

Rheumatology therapeutics encompass treatments aimed at managing and alleviating symptoms of rheumatic diseases, such as arthritis, lupus, and gout. These therapies include medications, such as anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs), and biologics, as well as physical therapy and lifestyle modifications. The goal is to reduce inflammation, control pain, and improve the quality of life for patients.

Browse Through More Similar Reports By The Business Research Company:

Cystic Fibrosis (CF) Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cystic-fibrosis-cf-therapeutics-global-market-report

Hepatitis Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

Peptide Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

What Will Be the Growth Trajectory of the Rheumatology Therapeutics Market from 2024 to 2033?

The rheumatology therapeutics market has shown steady growth in recent years. It is projected to increase from $40.45 billion in 2023 to $42.40 billion in 2024, with a CAGR of 4.8%. The historic growth is linked to the rising prevalence of rheumatologic disorders, the growing aging population globally, increased awareness of treatment options, advancements in biological therapies, and expanded healthcare access in emerging markets.

The rheumatology therapeutics market is anticipated to grow steadily in the coming years, projected to reach $51.42 billion in 2028, with a CAGR of 4.9%. This growth can be attributed to the shift toward personalized medicine, the rising adoption of biosimilars in rheumatology, increased investments in research and development, the integration of digital health technologies, and regulatory approvals for novel therapies. Key trends include the growth of telemedicine and remote monitoring solutions, the expansion of targeted therapies for specific rheumatic conditions, an emphasis on patient-centric care models, a broader range of biologic treatments beyond monoclonal antibodies, and the adoption of value-based pricing models.

What Are the Primary Growth Drivers for the Rheumatology Therapeutics Market?

The increasing incidence of autoimmune diseases is expected to propel the growth of the rheumatology therapeutics market in the future. Autoimmune diseases occur when the immune system mistakenly attacks the body’s tissues. The prevalence of these diseases is on the rise due to genetic, environmental, and lifestyle factors, alongside greater awareness and improved diagnostic capabilities. Rheumatology therapeutics are necessary for managing inflammation, alleviating symptoms, and preventing damage caused by the immune system’s attack on the body. For example, in June 2024, the Australian Institute of Health and Welfare estimated that around 514,000 people in Australia, or 2.0% of the population, were living with rheumatoid arthritis in 2022. Rheumatoid arthritis accounted for 2.0% of the total disease burden and 16% of the burden for all musculoskeletal conditions in 2023. Therefore, the rising incidence of autoimmune diseases is driving the growth of the rheumatology therapeutics market.

Claim Your Free Sample of the Global Rheumatology Therapeutics Market Report Today!

https://www.thebusinessresearchcompany.com/sample.aspx?id=17246&type=smp

What Are the Defining Segments of the Rheumatology Therapeutics Market?

The rheumatology therapeutics market covered in this report is segmented –

1) By Drug Class: Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Disease Indication: Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis, Other Disease Indications

What Trends Are Revolutionizing Standards in the Rheumatology Therapeutics Market?

Major firms in the rheumatology therapeutics market are focusing on innovative solutions like intravenous (IV) formulations to improve treatment efficacy. An IV formulation refers to medications administered directly into a vein. For example, in October 2023, Novartis AG announced that the US FDA approved Cosentyx, an IV formulation specifically for treating adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA), uniquely targeting interleukin-17A (IL-17A).

Order Now for Fast Delivery of Your Rheumatology Therapeutics Market Report!

https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

What Regions Are Propelling Growth in the Rheumatology Therapeutics Industry?

North America was the largest region in the rheumatology therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rheumatology therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Rheumatology Therapeutics Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the rheumatology therapeutics market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Rheumatology Therapeutics Market Include

1. Rheumatology Therapeutics Market Executive Summary
2. Rheumatology Therapeutics Market Segments
3. Rheumatology Therapeutics Market Size And Template Market Growth Rate
4.  Key Rheumatology Therapeutics Market Trends
5. Major Rheumatology Therapeutics Market Drivers
……
25. Key Mergers And Acquisitions In The Rheumatology Therapeutics Market
26. Top Rheumatology Therapeutics Companies
27. Rheumatology Therapeutics Market Opportunities And Strategies
28. Rheumatology Therapeutics Market, Conclusions And Recommendations
29. Appendix

Discover Related Reports by The Business Research Company:

Rheumatoid Arthritis Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report

Artificial Intelligence In Robotics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-robotics-global-market-report

Bipolar Disorder Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bipolar-disorder-therapeutics-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Industry: Pharmaceuticals

Meta Keywords:
Meta description:
Tags: Global Rheumatology Therapeutics Market, Global Rheumatology Therapeutics Market Report, Global Rheumatology Therapeutics Market Trends, Global Rheumatology Therapeutics Market Size

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

The rheumatology therapeutics market is on a steady growth trajectory, driven by increasing prevalence of autoimmune diseases, advancements in treatment options, and expanding healthcare access. Here’s an in-depth look at the market dynamics, projections, and key trends shaping the industry.

Current Market Size and Growth

• 2023 Market Size: $40.45 billion
• 2024 Market Size (Projected): $42.40 billion
• CAGR: 4.8%

Key Growth Drivers

• Rising Prevalence of Rheumatologic Disorders: Increased incidence of autoimmune diseases drives demand for therapeutics.
• Aging Population: Global aging population contributes to higher prevalence of rheumatologic conditions.
• Growing Awareness: Increased awareness about treatment options and advancements in biological therapies.
• Expansion of Healthcare Access: Improved access to healthcare in emerging markets boosts market growth.

View More On The Rheumatology Therapeutics Market Report 2024 –
https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

Future Market Growth and Trends

The rheumatology therapeutics market is expected to continue growing steadily, supported by various factors.

Forecasted Growth (2024-2028)

• CAGR: 4.9%
• 2028 Market Size (Projected): $51.42 billion

Growth Drivers

• Shift Towards Personalized Medicine: Adoption of personalized medicine approaches tailored to individual patient needs.
• Rising Adoption of Biosimilars: Increased use of biosimilars in rheumatology to enhance treatment options.
• Investment in Research and Development: Higher R&D investments lead to the development of innovative therapies.
• Integration of Digital Health Technologies: Digital tools and telemedicine enhance patient monitoring and treatment management.
• Regulatory Approvals for Novel Therapies: New therapies receive regulatory approvals, expanding treatment options.

Major Trends

• Telemedicine and Remote Monitoring Solutions: Growth in telehealth and remote patient monitoring for managing rheumatologic conditions.
• Expansion of Targeted Therapies: Development of targeted therapies for specific rheumatic conditions.
• Patient-Centric Care Models: Emphasis on care models that prioritize patient needs and outcomes.
• Biologic Treatments Beyond Monoclonal Antibodies: Expansion of biologic treatments to include newer therapeutic options.
• Value-Based Pricing Models: Adoption of pricing models focused on the value delivered by treatments.

Market Driver: Increasing Autoimmune Disease Prevalence

The growing prevalence of autoimmune diseases is a significant driver for the rheumatology therapeutics market.

Key Statistics

• June 2024: According to the Australian Institute of Health and Welfare, approximately 514,000 people in Australia were estimated to have rheumatoid arthritis in 2022, accounting for 2.0% of the total population and 16% of the burden for all musculoskeletal conditions.

Major Players in the Global Market

Leading companies in the rheumatology therapeutics market are driving innovation and expanding their market presence.

Key Companies

• Pfizer Inc.
• Johnson & Johnson
• Roche Holding AG
• Merck & Co. Inc.
• AbbVie Inc.
• Sanofi SA
• Janssen Biotech
• Regeneron Pharmaceuticals Inc.
• Biogen Inc.
• Vertex Pharmaceuticals
• UCB S.A.
• Galapagos NV (GLPG)
• Genentech Inc.

Innovations and Strategic Investments

Key players are focusing on advancements and strategic acquisitions to strengthen their market positions.

Example: Novartis AG

• October 2023: Announced FDA approval for Cosentyx, an intravenous (IV) formulation for treating psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. This formulation targets interleukin-17A (IL-17A) and is the only non-TNF-alpha IV treatment available for these conditions.

Example: Alfasigma S.p.A.

• February 2024: Acquired Jyseleca (filgotinib) from Galapagos NV for $184.54 million. This acquisition expands Alfasigma’s product portfolio in gastrointestinal and rheumatological treatments and enhances its presence in European markets.

Market Segmentation

The rheumatology therapeutics market is segmented into various categories:

1. By Drug Class:
   • Disease Modifying Anti-Rheumatic Drugs (DMARDs)
   • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
   • Corticosteroids
   • Uric Acid Drugs
   • Other Drug Classes
2. By Distribution Channel:
   • Hospital Pharmacy
   • Retail Pharmacy
   • Online Pharmacy
3. By Disease Indication:
   • Rheumatoid Arthritis
   • Osteoarthritis
   • Gout
   • Psoriatic Arthritis
   • Ankylosing Spondylitis
   • Other Disease Indications

Regional Insights

Regional dynamics highlight North America as the largest market, with significant growth potential in other regions.

Regional Market Leaders

• North America: The largest region in the rheumatology therapeutics market in 2023, driven by advanced healthcare infrastructure and high treatment adoption rates.
• Asia-Pacific: Expected to be the fastest-growing region during the forecast period due to expanding healthcare infrastructure and rising prevalence of rheumatologic disorders.

Request A Sample Of The Global Rheumatology Therapeutics Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=17246&type=smp